Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PRKCI | P41743 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553416 | 0.90 | ALDH1A1 (0.43) | MEN1KMT2APRKCIALDH1A1KIF11 | |
| SCHEMBL6079794 | 0.87 | MEN1 (0.41) | MEN1KMT2APRKCIHTTALDH1A1 | |
| SCHEMBL17682674 | 0.85 | POLB (0.45) | MEN1KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL6502347 | 0.84 | PRKCI (0.53) | MEN1KMT2APRKCIHTTALDH1A1 | |
| SCHEMBL28758020 | 0.78 | NR3C2 (0.49) | HTTALDH1A1 | |
| SCHEMBL3560505 | 0.76 | CYP1A2 (0.41) | MEN1KMT2AALDH1A1MAPTCYP1A2 | |
| SCHEMBL3561164 | 0.75 | KDM4E (0.35) | MEN1KMT2APRKCIHTTALDH1A1 | |
| SCHEMBL23432669 | 0.74 | NOS3 (0.39) | NOS3NOS2LMNA | |
| SCHEMBL29739556 | 0.74 | RAB9A (0.53) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL1425022 | 0.74 | HTT (0.43) | MEN1KMT2AHTTNOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1856305-B | Pyridine derivatives as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD | 2010-04-28 | — | — | CN | disclosed |
| CN-1856305-A | Pyridine derivatives and their use as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-01 | — | — | CN | disclosed |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | P2RY4, P2RX4, REN | MEN1 871/4885KMT2A 3136/4885PRKCI 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.